SCHEDULE: FMR LLC Discloses 2.1% Stake in Teva Pharmaceuticals
Beneficial Ownership Report
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 2.1% beneficial ownership stake in Teva Pharmaceutical Industries Ltd. as of September 30, 2025.
Summary
- FMR LLC and Abigail P. Johnson jointly filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in Teva Pharmaceutical Industries Ltd.
- They beneficially own an aggregate of 24,641,361.35 shares of Teva Pharmaceutical Industries Ltd. common stock.
- This ownership represents 2.1% of the total class of securities.
- FMR LLC holds sole voting power over 21,233,240.62 shares and sole dispositive power over 24,641,361.35 shares.
- Abigail P. Johnson holds sole dispositive power over 24,641,361.35 shares, but no sole or shared voting power.
- The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Teva Pharmaceutical Industries Ltd.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of beneficial ownership by a large institutional investor. It indicates a continued, but not controlling, stake in Teva Pharmaceutical Industries Ltd. The sentiment is neutral as it does not signal any significant strategic shift or performance update, merely a reporting of existing ownership.
Positives
- NA
Negatives
- NA
Risks
- The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating immediate control-related risks from these specific holders.
Future Outlook
NA
Management Comments
- The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.
Industry Context
This filing indicates continued institutional interest from a major asset manager (FMR LLC, parent of Fidelity) in Teva Pharmaceutical Industries. Teva is a global pharmaceutical company, and such disclosures are routine for large institutional investors maintaining positions, providing transparency on significant holdings within the sector.
Comparison to Industry Standards
- NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Statement of Intent | The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Teva Pharmaceutical Industries Ltd. | 09/30/2025 | This statement clarifies that the beneficial ownership is passive and not indicative of an activist stance or an attempt to alter corporate governance at Teva. |
Stakeholder Impact
- Shareholders: Provides transparency on significant institutional holdings, which can influence market perception and liquidity.
- Employees, Customers, Suppliers, Creditors: Minimal direct impact as the filing is a passive ownership disclosure and does not indicate operational changes or strategic shifts.
Key Dates
| Date | Description |
|---|---|
| 01/03/2023 | Effective date of Power of Attorney for FMR LLC. |
| 01/10/2023 | Date of Schedule 13G filing by FMR LLC (accession number -23-000003) where FMR LLC's Power of Attorney is incorporated by reference. |
| 01/26/2023 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 01/31/2023 | Date of Schedule 13G filing by FMR LLC (accession number -23-000038) where Abigail P. Johnson's Power of Attorney is incorporated by reference. |
| 09/30/2025 | Date of event which requires filing of this statement (beneficial ownership snapshot). |
| 11/04/2025 | Date of filing. |
Recommendation
holdThis Schedule 13G filing is a routine disclosure of beneficial ownership by FMR LLC and Abigail P. Johnson, indicating a 2.1% stake in Teva Pharmaceutical Industries Ltd. The filing explicitly states that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control. As such, it provides no new fundamental information about Teva's operational performance, strategic direction, or financial health that would warrant a change in investment thesis. Investors should continue to hold based on their existing analysis of Teva's business fundamentals, as this filing does not present a catalyst for a 'buy' or 'sell' decision.
Keywords
Teva Pharmaceutical Industries, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Pharmaceutical, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.